Closing

1D

YTD

Market cap

-

52 week high

-

52 week low

-

Volume

-

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

-

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

-

Operating Margin

-

Beta

-

Revenue Growth (Annual)

-

52 week high

-

52 week low

-

Div. Yield

-

EPS Annual Growth

-

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral EP delivery devices, such as the OncoSec Medical System (OMS) EP device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO) with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.